Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Nilesh-Gupta"

37 News Found

Lupin appoints Christoph Funke as Chief Technical Operations Officer
People | March 18, 2024

Lupin appoints Christoph Funke as Chief Technical Operations Officer

Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science


Lupin launches Vilfuro-G for COPD Management in India
News | November 23, 2023

Lupin launches Vilfuro-G for COPD Management in India

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide


Lupin Mandideep plant gets USFDA green signal
Drug Approval | November 01, 2023

Lupin Mandideep plant gets USFDA green signal

The inspection of the facility conducted from August 7 to August 11, 2023


Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 manufacturing facility
Drug Approval | September 30, 2023

Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 manufacturing facility

The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated


Lupin acquires five brands from Menarini
News | September 23, 2023

Lupin acquires five brands from Menarini

Lupin has been exclusively marketing these brands in the Indian market since July 2021


Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India
News | August 19, 2023

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes


Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
Drug Approval | August 16, 2023

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.


Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
News | June 30, 2023

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully


Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
News | June 21, 2023

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence


Lupin receives EIR from FDA for its API manufacturing facility in Vizag
Drug Approval | June 19, 2023

Lupin receives EIR from FDA for its API manufacturing facility in Vizag

The inspection closed with the facility receiving an inspection classification of NAI